Eleven Biotherapeutics Culture Company

Dr. Karl Dane Wittrup, Ph.D. co-founded Adimab, LLC (Adimab, Inc) in 2007 and served as its Member of the Office of the Chief Scientific Officer until June 8, 2017. Mr. Wittrup co-founded BioDisplay Technologies (acquired by Abbott Laboratories 2001) and Eleven Biotherapeutics Inc. He was acting Chief Scientific Officer at Adimab. He served as Principal Investigator of Panacea Pharmaceuticals, Inc. He served as postdoctoral research associate in Amgen's Yeast Molecular Biology Group. Dr. Wittrup is a pioneer in protein engineering technologies and an expert in the science of targeting cancer with antibodies. He also serves as Chairman of the SAB e-mail. He serves as the Chairman and a Member of the Scientific Advisory Board of Adimab, Inc. He serves as Member of Scientific Advisory Board at Permeon Biologics Inc. He is the Associate Director of MIT's Koch Institute. He is Professor in Medical Microbiology at the University Clinic in D'sseldorf, Germany. Dr. Wittrup serves as a Member of Scientific Advisory Board at Eleven Biotherapeutics, Inc. He serves as a Member of Scientific Advisory Board at Dragonfly Therapeutics, Inc. Dr. Wittrup served as Member of Scientific Advisory Board of Arsanis Inc. until January 12, 2017. His work is published in over 200 scientific papers and he has authored several reviews and books on antibiotic resistance. He is the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT. Dr. Wittrup has also served as the J. W. Westwater Professor of Chemical Engineering, Biophysics and Bioengineering at the University of Illinois at Urbana-Champaign. Dr. Wittrup is a fellow of the American Institute of Biomedical Engineers. He holds a Ph.D. and M.S. in Chemical Engineering from the California Institute of Technology and a B.S. in Chemical Engineering from the University of New Mexico.

Dr. Gregory L. Verdine, also known as Greg, Ph.D., serves as the Chief Executive Officer and President of Fog Pharmaceuticals, Inc. Dr. Verdine serves as President and Executive Director at LifeMine Therapeutics, Inc. Dr. Verdine is a Co-Founder of Warp Drive Bio, LLC and serves as its Chairman of The Scientific Advisory Board. Dr. Verdine is the founder of Verdyne Partners LLC and serves as its President and Chief Executive Officer. He is a Co-Founder at Eleven Biotherapeutics Inc and Tokai Therapeutics. He is a thought leader in the field of chemical biology and an accomplished drug discovery entrepreneur. He serves as a Venture Partner at Wuxi Healthcare Ventures since May 3, 2016. He serves as Senior Advisor of Shin Nippon Biomedical Laboratories, or SNBL. He is the Scientific Founder at Enanta. Dr. Verdine served as the President of Warp Drive Bio, LLC and also served as its Chief Scientific Officer until April 6, 2016. He served as the Chief Executive Officer of Warp Drive Bio, LLC from July 2013 to March 2015. He was Venture Partner of Apple Tree Partners I, L.P and Apple Tree Partners II L.P. Dr. Verdine Co-founded Gloucester Pharmaceuticals Inc in 2003 and served as its Scientific Advisor. Dr. Verdine served as Scientific Advisor of Enanta Pharmaceuticals, Inc. He serves as a Scientific Consultant to Roche Pharmaceuticals. Dr. Verdine served as the Interim Chief Scientific Officer at WarpDriveBio. He was the Founder of Tokai Pharmaceuticals, Inc. Dr. Verdine joined Third Rock Ventures in 2009 and provides scientific due diligence for its potential portfolio investments. Dr. Verdine co-founded a number of biotechnology companies including Enanta Pharmaceuticals, Inc. Aileron Therapeutics, Tokai Pharmaceuticals, Ontorii Pharmaceuticals and Eleven Biotherapeutics. For more than a decade, he served as one of two global consultants for Hoffmann-La Roche and was a Founding Scientific Advisor to Vertex Pharmaceuticals Incorporated, Ariad Pharmaceuticals and Variagenics, Inc. He served as Venture Partner of Third Rock Ventures, LLC. Dr. Verdine was also a Venture Partner of Apple Tree Partners, which he joined in 2003. He serves as the Chairman of Scientific Advisory Board at ShangPharma Corporation. He served as Chairman at WAVE Life Sciences Ltd. since July 2013 until October 16, 2017 and its Director since 2012. He served as the Chairman of Scientific Advisory Board at Gloucester Pharmaceuticals inc. Dr. Verdine served as Chairman of Scientific Advisory Board of Aileron Therapeutics, Inc. He serves as a Director of Warp Drive Bio, LLC. He serves as a Member of Advisory Board at Spinal Muscular Atrophy Foundation. Dr. Verdine serves as Member of Board of Reviewers at Bill & Melinda Gates Foundation. He is Member of Board of Scientific Consultants at Memorial Sloan-Kettering Cancer Center. He serves as Member of Scientific Advisory Board at Amphora Discovery Corporation. Dr. Verdine serves as a Member of Science & Medical Advisor at N-of-One, Inc. He was Member of Scientific Advisory Board at FORUM Pharmaceuticals Inc. (EnVivo Pharmaceuticals, Inc). He serves as a Director of Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute. Dr. Verdine is a director of Gloucester Marine Genomics Institute, which he co-founded in 2013. Dr. Verdine was a Director of Gloucester Pharmaceuticals, Inc. He was a Director of Aileron Therapeutics, Inc. He is a Harvard Professor and the Erving Professor of Chemistry in the departments of Stem Cell and Regenerative Biology, Chemistry, Chemical Biology and Molecular and Cellular Biography at Harvard University for the past 25 years. Dr. Verdine is a founding Faculty Member of the Harvard Institute Chemistry and Cell Biology. He served as a NIH Postdoctoral Fellow in Molecular Biology at MIT and Harvard Medical School. He discovered the molecular mechanism of epigenetic DNA methylation and elucidated the pathway by which certain genotoxic forms of DNA damage are eradicated from the genome. Dr. Verdine is also responsible for having developed a new class of therapeutics termed stapled peptides, which are in clinical development and have received much attention for their ability to drug ???undruggable??? targets. He serves as a Director at Fog Pharmaceuticals, Inc. and LifeMine Therapeutics, Inc. He serves as a Scientific Advisor to the Board of Directors of the Ibusuki Medipolis Research Institute; the Bill and Melinda Gates Foundation; the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center (Memorial Sloan Kettering Research Institute); on the board of scientific advisors of the National Cancer Institute; and the Scientific Advisory Board of the SMA Foundation. He served as a Director of Enanta Pharmaceuticals, Inc. from 1996 to August 18, 2013. He is a VIP Faculty Member at the Agency of Science and Technology Research (A*STAR) in Singapore and a Guest Professor at Peking University. Dr. Verdine is a Lilly Award winner in Biological Chemistry. He was a National Institutes of Health postdoctoral fellow in molecular biology at the Massachusetts Institute of Technology and Harvard Medical School. Dr. Verdine received a Ph.D. in Organic Chemistry from Columbia University and a B.S. in Chemistry from St. Joseph's University.

Dr. K. Christopher Garcia, also known as Chris, Ph.D., is a Co-founder of Eleven Biotherapeutics Inc. Dr. Garcia has been a Professor of Molecular and Cellular Physiology and of Structural Biology at Stanford University School of Medicine since 1999 and an investigator with the Howard Hughes Medical Institute since 2005. Dr. Garcia is a leading scientist studying the structural biology of cytokine receptor recognition and activation and probing cytokine signaling mechanisms using protein engineering. His research has identified new paradigms for recognition and activation of a variety of receptors that play critical roles in autoimmunity, cancer, neural growth and repair and blood pressure regulation. His laboratory also has a longstanding interest in the structural biology of adaptive immunity, mainly focused on understanding on how the T cell receptor recognizes MHC molecules. Dr. Garcia serves as a Member of Scientific Advisory Board at Eleven Biotherapeutics, Inc., and NGM Biopharmaceuticals, Inc. Dr. Garcia serves as Member of Scientific Advisory Board at Dragonfly Therapeutics, Inc. He served as Member of Scientific Advisory Board at Immune Disease Institute, Inc. He was elected to the National Academy of Sciences in 2012. Dr. Garcia was elected to the National Academy of Medicine. Dr. Garcia holds a Ph.D. in Biophysics from Johns Hopkins University School of Medicine and a B.S. in Biochemistry from Tulane University. He was a postdoctoral fellow at Genentech and Scripps Research Institute.

Dr. Reza Dana M.D., MPH, M.Sc is the Founder of Eleven Biotherapeutics, Inc. Dr. Dana serves as Co-Director of Research at Schepens Eye Research Institute Inc. He serves as Senior Scientist and W. Clement Stone Scholar in The Schepens Eye Research Institute. He also serves as a Director of the Cornea Service at The Massachusetts Eye and Ear Infirmary. He serves as Senior Editor to Encyclopedia of the Eye. He serves on the Editorial Board of the journals Investigative Ophthalmology and Visual Science (IOVS), Cornea, The Ocular Surface, Ophthalmologica, and UpToDate (Rheumatology and Allergy). He served as a Member of Ophthalmic Advisory Board at NovaBay Pharmaceuticals, Inc. since 2012. Dr. Dana is Professor of Ophthalmology and the Claes Dohlman Chair in Ophthalmology at Harvard Medical School. Dr. Dana serves as a Member of Scientific Advisory Board at Eleven Biotherapeutics, Inc. He is an Ophthalmologist and an Immunologist, with a particular interest in the molecular and cellular mechanisms of inflammation and immunity in the eye and ocular surface. He published over 250 peer-reviewed journal articles, book chapters and books. Dr. Dana is a recipient of multiple awards, including the Research to Prevent Blindness (RPB) William and Mary Greve Special Scholar Award, the RPB Physician-Scientist Award, the RPB Lew R. Wasserman Merit Award, the Achievement Award of the American Academy of Ophthalmology and the Cogan Award of the Association for Research in Vision and Ophthalmology, for his many contributions to the field of ophthalmology and ophthalmic science. He performed his residency in Ophthalmology at the Illinois Eye and Ear Infirmary in Chicago, followed by fellowship training at the Wills Eye Hospital in Philadelphia (Cornea and External Diseases), Massachusetts Eye and Ear Infirmary (Ocular Immunology and Uveitis) and Schepens Eye Research Institute (Transplantation Immunology) at Harvard Medical School. Dr. Dana received his Bachelor's, graduate, and Medical degrees from Johns Hopkins University, and his Master of Science degree from Harvard University.

Gregory Adams serves as the Chief Scientific Officer of Eleven Biotherapeutics. Gregory started at Eleven Biotherapeutics in Jan of 2017. Gregory currently resides in the Greater Philadelphia Area.

Jay Duker serves as the Director of Eleven Biotherapeutics. Jay started at Eleven Biotherapeutics in February of 2015. Jay currently resides in the Greater Boston Area.

Dennis Kim serves as the Chief Medical Officer of Eleven Biotherapeutics. Dennis started at Eleven Biotherapeutics in December of 2018. Dennis currently resides in the Greater New York City Area.